A groundbreaking real-world study emerging from The University of Texas MD Anderson Cancer Center has revealed that mail-in, self-collection tests for human papillomavirus (HPV) significantly enhance cervical cancer screening participation among underserved women in the United States. This novel approach, detailed in the PRESTIS randomized trial, highlights a promising pathway to combat longstanding disparities in cervical cancer detection and prevention. The results demonstrated that women offered self-collection kits were more than twice as likely to engage in screening compared to those who received standard telephone reminders alone, marking an important advance in public health outreach strategies.
Cervical cancer, predominantly caused by persistent infection with high-risk HPV strains, remains a critical health concern, especially among never- or under-screened populations. These groups often include uninsured individuals, women residing in rural areas, and minorities disproportionately affected by socioeconomic barriers. Traditional screening relies heavily on clinic-based Pap tests or clinician-administered HPV tests, which can pose significant access challenges. By incorporating home-based self-collection testing, the PRESTIS study effectively dismantled some of these barriers, demonstrating that accessibility and convenience play pivotal roles in patient engagement and timely cancer screening.
The PRESTIS study enrolled nearly 2,500 women aged 30 to 65 from the Houston metropolitan area between 2020 and 2023. Participants were predominantly from racial and ethnic minoritized groups and many were covered by publicly funded health assistance programs. The trial compared three distinct intervention arms: a conventional telephone reminder encouraging clinic-based screening, a telephone reminder paired with a mailed self-collection HPV test kit, and a combination of a telephone reminder, self-collection kit, plus patient navigation services designed to support and guide participants through the screening process. This layered design allowed researchers to gauge not only the impact of self-collection but also the added benefits of personalized patient engagement.
Findings published in JAMA Internal Medicine indicated that 41% of women receiving both the telephone reminder and self-collection kit participated in screening within six months, dramatically surpassing the 17% participation observed in the telephone reminder-only group. The inclusion of patient navigation further amplified screening rates to 47%, underscoring the value of tailored support in overcoming logistical or informational obstacles. Furthermore, over 80% of women in the self-collection arms returned their kits, showcasing strong acceptability and feasibility of at-home specimen collection among diverse and underserved populations.
Jane Montealegre, Ph.D., associate professor of Behavioral Science and lead investigator, emphasizes the profound implications of these results. According to Dr. Montealegre, “Self-collection testing holds transformative potential for increasing access to cervical cancer screening, particularly for communities facing systemic healthcare inequities.” Her team’s research suggests that integrating self-collection into routine care may serve as a crucial mechanism to reduce cervical cancer incidence and mortality, especially in hard-to-reach groups historically neglected in public health initiatives.
The timing of this study is particularly significant, as May 2025 marked the FDA’s approval of the first at-home screening test for cervical cancer. This regulatory milestone validates the clinical utility of self-collection testing and opens the door for widespread implementation. Given that cervical cancer affects approximately 13,000 women annually in the U.S., predominantly those lacking regular screening access, self-collected HPV testing could fundamentally shift screening paradigms from clinic-centric models toward patient-empowered approaches.
Persistent disparities in cervical cancer screening and outcomes remain a public health challenge, with racial and ethnic minorities and rural populations experiencing disproportionate disease burden. While HPV vaccination campaigns and widespread Pap screening have markedly decreased overall cervical cancer rates over recent decades, these improvements have not been equitably distributed. The PRESTIS study addresses this gap by targeting populations less likely to engage with traditional health care systems, illustrating how innovative service delivery models can bridge systemic divides.
Biologically, HPV is recognized as the necessary cause of virtually all cervical cancers. High-risk HPV genotypes integrate into cervical epithelial cells, initiating molecular pathways that can progress to dysplasia and invasive cancer over years. Early detection through screening allows for the identification and treatment of precancerous lesions, preventing malignant transformation. Mailing self-collection kits enables women to obtain cervicovaginal samples without clinic visits, potentially increasing compliance with screening guidelines and facilitating early diagnoses.
Despite the promising outcomes, the study also acknowledges limitations: external influences from the COVID-19 pandemic may have affected healthcare-seeking behaviors during the trial period; reasons for refusal to participate in screening were not fully elucidated; and logistical challenges associated with mailing kits warrant further examination. Additionally, the trial did not assess clinical follow-up procedures for women testing positive for high-risk HPV via self-collected samples, an area requiring future research to optimize patient pathways from screening to treatment.
Looking ahead, Dr. Montealegre and her collaborators plan to explore integration strategies for self-collection HPV testing in diverse primary care settings. Understanding how to implement this approach effectively across various health systems will be critical for scalability and sustainability. Emphasis will be placed on identifying best practices for patient education, specimen processing, and provider workflows to ensure that increased screening rates translate into meaningful reductions in cervical cancer morbidity and mortality.
The study’s support came from multiple grants by the National Institutes of Health, including targeted funding from the National Institute for Minority Health and the National Cancer Institute, underscoring the importance of addressing health disparities through rigorous scientific inquiry. The PRESTIS trial represents a significant step forward in aligning evidence-based interventions with social justice goals, merging medical innovation with health equity principles.
In conclusion, these compelling findings elucidate the potential for self-collection HPV testing to revolutionize cervical cancer screening among underserved populations in the United States. By enhancing accessibility, increasing participation rates, and fostering patient autonomy, this approach can serve as a powerful tool in the ongoing effort to eliminate preventable cervical cancer deaths. As regulatory approvals expand and implementation frameworks mature, self-collection testing may soon become an integral component of comprehensive cancer prevention strategies nationwide.
Subject of Research: Increasing cervical cancer screening participation through mail-in self-collection HPV testing in underserved U.S. populations.
Article Title: Self-Collection HPV Testing Doubles Cervical Cancer Screening Participation Among Underserved Women: Results from the PRESTIS Study
News Publication Date: June 6, 2025
References:
Trial funding and details are from National Institutes of Health grants: R01MD30175, P30CA016672, P30CA125123, P30CA138313
Image Credits:
Credit: The University of Texas MD Anderson Cancer Center
Keywords:
Cancer, Cervical Cancer, HPV, Screening, Self-Collection, Public Health, Health Disparities, Behavioral Science
